Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.

The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis

Open access

Abstract

The objective of this systematic literature review was to determine the association between cardiovascular events (CVEs) and antirheumatic drugs in rheumatoid arthritis (RA) and psoriatic arthritis (PsA)/psoriasis (Pso). Systematic searches were performed of MEDLINE, EMBASE and Cochrane databases (1960 to December 2012) and proceedings from major relevant congresses (2010-2012) for controlled studies and randomised trials reporting confirmed CVEs in patients with RA or PsA/Pso treated with antirheumatic drugs. Random-effects meta-analyses were performed on extracted data. Out of 2630 references screened, 34 studies were included: 28 in RA and 6 in PsA/Pso. In RA, a reduced risk of all CVEs was reported with tumour necrosis factor inhibitors (relative risk (RR), 0.70; 95% CI 0.54 to 0.90; p=0.005) and methotrexate (RR, 0.72; 95% CI 0.57 to 0.91; p=0.007). Non-steroidal anti-inflammatory drugs (NSAIDs) increased the risk of all CVEs (RR, 1.18; 95% CI 1.01 to 1.38; p=0.04), which may have been specifically related to the effects of rofecoxib. Corticosteroids increased the risk of all CVEs (RR, 1.47; 95% CI 1.34 to 1.60; p<0.001). In PsA/Pso, systemic therapy decreased the risk of all CVEs (RR, 0.75; 95% CI 0.63 to 0.91; p=0.003). In RA, tumour necrosis factor inhibitors and methotrexate are associated with a decreased risk of all CVEs while corticosteroids and NSAIDs are associated with an increased risk. Targeting inflammation with tumour necrosis factor inhibitors or methotrexate may have positive cardiovascular effects in RA. In PsA/Pso, limited evidence suggests that systemic therapies are associated with a decrease in all CVE risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2014-206624

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Search and selection of studies for systematic review and meta-analysis. PsA, psoriatic arthritis; Pso, psoriasis; RA, rheumatoid arthritis.
Figure 1 Search and selection of studies for systematic review and meta-analysis. PsA, psoriatic arthritis; Pso, psoriasis; RA, rheumatoid arthritis.CC BY-NC · PubMed Central
Figure 2 Meta-analyses of all cardiovascular events and individual cardiovascular events in patients with rheumatoid arthritis treated with (A) tumour necrosis factor inhibitors; (B) methotrexate; (C) non-steroidal anti-inflammatory drugs; or (D) corticosteroids in controlled studies. Size of data markers indicates relative weight of the study (from random-effects analysis). COX-2, cyclooxygenase-2; CVE, cardiovascular event; MACE, major adverse cardiac event; MTX, methotrexate; RR, relative risk; TNFi, tumour necrosis factor inhibitor.
Figure 2 Meta-analyses of all cardiovascular events and individual cardiovascular events in patients with rheumatoid arthritis treated with (A) tumour necrosis factor inhibitors; (B) methotrexate; (C) non-steroidal anti-inflammatory drugs; or (D) corticosteroids in controlled studies. Size of data markers indicates relative weight of the study (from random-effects analysis). COX-2, cyclooxygenase-2; CVE, cardiovascular event; MACE, major adverse cardiac event; MTX, methotrexate; RR, relative risk; TNFi, tumour necrosis factor inhibitor.CC BY-NC · PubMed Central
Figure 3 Funnel plots for the meta-analysis of occurrence of cardiovascular events associated with treatment with (A) tumour necrosis factor inhibitors, (B) methotrexate, (C) non-steroidal anti-inflammatory drugs and (D) corticosteroids. The importance (weight) of each study is proportional to the marker size.
Figure 3 Funnel plots for the meta-analysis of occurrence of cardiovascular events associated with treatment with (A) tumour necrosis factor inhibitors, (B) methotrexate, (C) non-steroidal anti-inflammatory drugs and (D) corticosteroids. The importance (weight) of each study is proportional to the marker size.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 71 references

Research works printed but not linked: 4

  1. Low, 2012, Association between anti-tumor necrosis factor therapy and the risk of ischemic stroke in subjects with rheumatoid arthritis. Results from the British Society For Rheumatology Biologics Registers-Rheumatoid Arthritis (BSRBR-RA). [abstract], Arthritis Rheum, 64, 828
  2. Anandarajah, 2012, Major adverse cardiovascular events are more common in rheumatoid arthritis than in psoriatic arthritis and are associated with different risk factors. [abstract], Arthritis Rheum, 64, 2221
  3. Bozaite-Gluosniene, 2011, Reduced cardiovascular risk with use of methotrexate and tumor necrosis factor-inhibitors in patients with rheumatoid arthritis. [abstract], Arthritis Rheum, 63, 719
  4. Biki, 2011, Prolonged hydroxychloroquine use is associated with decreased incidence of cardiovascular disease in rheumatoid arthritis patients. [abstract], Arthritis Rheum, 63, 1168

Cited by

See all 907

Metadata

Authors
Roubille, C., Richer, V., Starnino, T., McCourt, C., McFarlane, A., Fleming, P., Siu, S., Kraft, J., Lynde, C., Pope, J., Gulliver, W., Keeling, S., Dutz, J., Bessette, L., Bissonnette, R., & Haraoui, B.
Affiliations
  • Hôpital Notre-Dame (CA)
  • Hôpital Saint-Luc (CA)
  • Hôpital du Sacré-Cœur de Montréal (CA)
  • University of British Columbia (CA)
  • University of Alberta (CA)
  • University of Toronto (CA)
  • Western University (CA)
  • Lynde Centre for Dermatology (CA)
  • Memorial University of Newfoundland (CA)
  • Université Laval (CA)
  • Innovaderm (Canada) (CA)
  • Centre Hospitalier de l’Université de Montréal (CA)
Corresponding author
Haraoui, Boulos
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2015-03
Volume
74
Issue
3
Pages
480-489
ISSN
0003-4967 (ISSN-L)
OpenAlex
W2169773326
Cited by
907
References
71
Citations by year
2026: 55 · 2025: 82 · 2024: 74 · 2023: 84 · 2022: 78 · 2021: 98 · 2020: 93 · 2019: 83 · 2018: 86 · 2017: 75 · 2016: 65 · 2015: 29
FWCI
13.16
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of the Rheumatic Diseases (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
British Association of Dermatologists
Topics
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
  • Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
Keywords
tumor necrosis factor inhibitors, methotrexate, nonsteroidal anti-inflammatory drugs, corticosteroids, cardiovascular events, rheumatoid arthritis, psoriatic arthritis, psoriasis, rofecoxib, cardiovascular risk, systemic therapy, inflammation-targeted therapy, drug safety, cardiovascular mortality, myocardial infarction, stroke, congestive heart failure
MeSH terms
Adrenal Cortex Hormones, Anti-Inflammatory Agents, Non-Steroidal, Arthritis, Rheumatoid, Cardiovascular Diseases, Humans, Methotrexate, Psoriasis, Risk Factors, Tumor Necrosis Factor-alpha, Arthritis, Psoriatic, Antirheumatic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1136/annrheumdis-2014-206624
The paper
Roubille, C., Richer, V., Starnino, T., McCourt, C., McFarlane, A., Fleming, P., Siu, S., Kraft, J., Lynde, C., Pope, J., Gulliver, W., Keeling, S., Dutz, J., Bessette, L., Bissonnette, R., & Haraoui, B. (2015). The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2014-206624

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.